Ascendis Pharma A/S Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement
Ascendis Pharma A/S (ASND) had Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement of EUR 29.03 as of 2018-12-31, per its 20-F filed 2019-04-03.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement · last filed 2019-04-03
- 2018-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement 29.03 EUR.
- 2017-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement 17.62 EUR.
- 2016-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement 13.05 EUR.
- 2015-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement 10.69 EUR.
| Period end | Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement |
|---|---|
| 2018-12-31 | 29.03 EUR 20-F · filed 2019-04-03 |
| 2017-12-31 | 17.62 EUR 20-F · filed 2018-03-28 |
| 2016-12-31 | 13.05 EUR 20-F · filed 2018-03-28 |
| 2015-12-31 | 10.69 EUR 20-F · filed 2018-03-28 |